About: Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
Creator	Zhao, Rong Wang, • Kong, Ruan, De-Guang, • Kong, Wen-Hua Liu, Man-Qing Qiong-Fang, • Sun, Jian-Bin Zhou, Jun-Bo
Source	Medline; PMC
abstract	The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17–83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1007/s12250-020-00270-x
bibo:pmid	32705575
has license	no-cc
sha1sum (hex)	8e64233f3ce51851740af4bce0fbefdbde0b8194
schema:url	https://doi.org/10.1007/s12250-020-00270-x
resource representing a document's title	Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
has PubMed Central identifier	PMC7376096
has PubMed identifier	32705575
schema:publication	Virol Sin
resource representing a document's body	covid:8e64233f3ce51851740af4bce0fbefdbde0b8194#body_text
is schema:about of	named entity 'linked' named entity 'immunological' named entity 'mild' named entity 'evidence' named entity 'commercial' named entity '0.001' named entity 'COVID-19' named entity '28P' named entity 'NAT' covid:arg/8e64233f3ce51851740af4bce0fbefdbde0b8194 named entity 'nucleic acid test' named entity 'Comparison' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'NAT' named entity 'confirmed' named entity 'combination' named entity 'serologic tests' named entity 'positive' named entity 'number' named entity 'IgM' named entity 'correlation' named entity 'ratio' named entity 'onset' named entity 'basic' named entity 'Patients' named entity 'serologic tests' named entity 'immunological' named entity 'IgM' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'seroconversion' named entity 'nucleic acid' named entity 'SARS-CoV-2' named entity 'serologic testing' named entity 'moderate group' named entity 'NMPA' named entity 'case-fatality rate' named entity 'throat swab' named entity 'coronavirus disease 2019' named entity 'IgG antibody' named entity 'clinical symptoms' named entity 'serum' named entity 'NAT' named entity 'informed consent' named entity 'Chi square test' named entity 'COVID' named entity 'significant difference' named entity 'IgG' named entity 'antibody' named entity 'IgM' named entity 'immune responses' named entity 'Centers for Disease Prevention and Control' named entity 'IgM' named entity 'IgG' named entity 'COVID-19' named entity 'IgG' named entity 'IgG antibody' named entity 'NAT' named entity 'clinical features' named entity 'potential difference' named entity 'Guangzhou' named entity 'COVID' named entity 'China' named entity 'qPCR' named entity 'CDC' named entity 'inflammation' named entity 'immunogenicity' named entity 'IgG antibodies' named entity 'serologic test' named entity 'IgG' named entity 'viral load' named entity 'multiple organ dysfunction'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software